Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M

Autolus Therapeutics plc

Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.
FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.
UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.
Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Autolus Therapeutics plc reported the quarter and full year ended December 31, 2025 results: revenue $23.3 million. Guidance reaffirmed.

Period: the quarter and full year ended December 31, 2025
Revenue: $23.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.